The drug, which can extend the lives of patients with a recurring and incurable cancer of the bone marrow cells – known as multiple myeloma – by an average of nine months, has been given the green light for routine use by NICE after it was made available for a limited period through the Cancer Drugs Fund. NHS England
No comments:
Post a Comment